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Abstract
Aim To evaluate the association with diabetic kidney disease of single nucleotide polymorphisms (SNPs) that may
contribute to mitochondrial dysfunction.
Methods The mitochondrial genome and 1039 nuclear genes that are integral to mitochondrial function were
investigated using a case (n = 823 individuals with diabetic kidney disease) vs. control (n = 903 individuals with
diabetes and no renal disease) approach. All people included in the analysis were of white European origin and were
diagnosed with Type 1 diabetes before the age of 31 years. Replication was conducted in 5093 people with similar
phenotypes to those of the discovery collection. Association analyses were performed using the PLINK genetic analysis
toolset, with adjustment for relevant covariates.
Results A total of 25 SNPs were evaluated in the mitochondrial genome, but none were significantly associated with
diabetic kidney disease or end-stage renal disease. A total of 38 SNPs in nuclear genes influencing mitochondrial function
were nominally associated with diabetic kidney disease and 16 SNPS were associated with end-stage renal disease,
secondary to diabetic kidney disease, with meta-analyses confirming the same direction of effect. Three independent
signals (seven SNPs) were common to the replication data for both phenotypes with Type 1 diabetes and persistent
proteinuria or end-stage renal disease.
Conclusions Our results suggest that SNPs in nuclear genes that influence mitochondrial function are significantly
associated with diabetic kidney disease in a white European population.
Diabet. Med. 32, 1104–1109 (2015)
Introduction
Diabetic kidney disease is a complex renal disorder repre-
senting a major global economic burden [1,2]. There is
an inherited genetic predisposition for diabetic kidney
disease, but the majority of studies to date have focused on
genetic variation in the nuclear genome [3]. Mitochondria
are specialized organelles that generate energy by oxidative
phosphorylation, but they are susceptible to oxidative
damage from cellular stress, including hyperglycaemia and
exposure to a uraemic environment. Chronic inflammation is
a common contributor to progressive renal failure and leads
to premature mitochondrial DNA (mtDNA) damage. Path-
ogenic mutations in mtDNA represent an increasingly
recognized cause of chronic morbidity, and mitochondrial
mutations have been implicated in a range of complex
disorders, including kidney disease [4–6]. There is a
synergistic relationship between the mitochondrial and
nuclear genomes, with the expression of nuclear genes being
essential for critical mitochondrial functions.
The aim of the present study was to investigate genetic
variation that may contribute to mitochondrial dysfunction,
both across the mitochondrial genome and in nuclear genes
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that affect mitochondrial function, using a case–control
approach, followed by independent replication.
Methods
Participants
Written informed consent was obtained from all individuals
in the discovery cohort who were recruited to the All-Ireland-
Warren 3-Genetics of Kidneys in Diabetes (GoKinD) UK
collections. Cases (n = 823) were white European individu-
als with Type 1 diabetes of at least 10 years duration, who
had persistent proteinuria ( > 500 mg/24 h), hypertension
( ≥ 135/85 mmHg) and retinopathy. End-stage renal disease
(n = 246), secondary to diabetic kidney disease, was defined
as requiring renal replacement therapy (chronic dialysis or
kidney transplantation). Control subjects (n = 903) were
people with at least 15 years’ duration of Type 1 diabetes,
with no evidence of renal disease on repeated testing. Control
subjects were not prescribed anti-hypertensive medication to
avoid misclassification of phenotype, as blood pressure-
lowering treatment may reduce proteinuria. The discovery
and replication groups have been previously described and
include the FinnDiane (Finland), GoKinD (USA), and Steno
Diabetes Centre (Denmark) cohorts (Table S1) [7]. In all,
3245 people with diabetic kidney disease, 1422 people with
end-stage renal disease and 3574 control subjects were
analysed in the present study.
Gene, single-nucleotide polymorphism selection and
genotyping
Twenty-five single nucleotide polymorphisms (SNPs) in the
mitochondrial genome were investigated using existing
genotype data from individuals genotyped using the
Omni1-quad array using a case vs control group approach
(Table S2) [7]. Relevant nuclear genes (n = 1096) were
extracted fromMITOCARTA [8] (n = 1012 genes) and MITOMAP
[9] (n = 84 genes). Downloaded gene lists were revised to
approved unique HUGO Gene Nomenclature Committee
[10] symbols, resulting in the removal of 57 duplicate gene
names; a total of 1039 unique nuclear genes were analysed.
The SNPs were downloaded from the Ensembl genome
browser [11] using Ensembl genes 74 database on the Homo
sapiens (GRCh37.p13) dataset. The SNPs (n = 9 243 501)
associated with 1039 genes in the nuclear genome that
influence mitochondrial function were investigated for their
association with diabetic kidney disease. Genotype data for
nuclear genes were extracted for relevant genes from
imputed, publicly accessible directly typed genome-wide
data for the discovery cohort (dbGaP Study Accession:
phs000389.v1.p1; [7]). In silico replication was conducted
for all top-ranked SNPs, where P ≤ 0.05 in the discovery
study when considering either diabetic kidney disease or end-
stage renal disease as the phenotype; data were retrieved
from the GENIE genome-wide association study meta-
analysis [7]. De novo genotyping was conducted for
replication of the top seven independent signals using
commercially available TaqMan 5’ nuclease assays (Life
Technologies, Warrington, UK) according to the manufac-
turer’s instructions.
Statistical analysis
Allelic association was adjusted for age, duration of diabetes,
gender and multiple testing using PLINK software (version
1.07 [12]) for de novo genotyping. PLINK (http://
pngu.mgh.harvard.edu/ ~ purcell/plink) is a free, open-
source whole-genome association analysis toolset, which
efficiently performs association studies for single SNPs or
computationally intensive genome-wide association studies.
Replication was conducted in silico for the FinnDiane
(n = 2910) and USA (n = 1595) populations, followed by
de novo genotyping in a Danish (n = 588) cohort. Genotype
data were evaluated for their association with diabetic
kidney disease and end-stage renal disease.
Results
Concordance between genotype duplicates (n = 12) was
100%, with genotype completion rates of > 89% for SNPs
in the mitochondrial genome and > 97.5% for SNPs in the
nuclear genome.
One mtDNA SNP was monomorphic in the UK collection;
MitoT9951C. A further 19 mtDNA SNPs were present with
a minor allele frequency ≤ 5%. Five SNPs were observed
with a minor allele frequency of > 5%, but no SNPs in the
mitochondrial genome were associated with diabetic kidney
disease (Table S2).
What’s new?
• Mitochondrial dysfunction has been identified in dia-
betic kidney disease, but relatively large-scale genetic
and epigenetic studies focused on mitochondria have
not yet been described.
• We report a novel case–control analysis, with indepen-
dent replication, of genetic variation focused on the
mitochondrial genome and 1039 nuclear genes that are
important for mitochondrial function.
• Single nucleotide polymorphisms (SNPs) in nuclear
genes affecting mitochondrial function were found to be
associated with diabetic kidney disease. The highlighted
SNPs were within the genes implicated in regulation of
epigenetic processes. Further research to explore the
interactions between hyperglycaemia, uraemia and
epigenetic modifications of the genome could shed
new light on how these nuclear genome SNPs are
associated with kidney disease.
ª 2015 The Authors.
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A total of 9 243 501 SNPs in mitochondrial-related
nuclear genes were downloaded from Ensembl [11]. A
comparison of 823 cases with Type 1 diabetes and nephrop-
athy with 903 control subjects with Type 1 diabetes and no
evidence of nephropathy identified 421 SNPs in 86 unique
genes with a nominal association (P ≤ 0.05) with diabetic
kidney disease, without correction for multiple testing. In
silico replication in the FinnDiane (n = 2910), and USA
(n = 1595) cohorts supported the association of 38 SNPs in
17 unique genes with consistent direction of effect across all
collections (Table S3). Consideration of the more extreme
phenotype of end-stage renal disease (246 cases vs. 903
controls) identified 139 SNPs in 50 unique genes where
P ≤ 0.05. In silico replication in the FinnDiane and GoKinD
USA cohorts supported the association of 16 SNPs in eight
genes (seven independent signals, P < 0.05), with a consis-
tent direction of effect observed across all three case–control
collections for end-stage renal disease (Table 1). SNPs were
investigated for regulatory features using HAPLOREG and
Blood eQTL browsers (Tables S4 and S5, respectively).
Seven SNPs (representing three independent signals) were
common to both diabetic kidney disease and end-stage renal
disease for the in silico replication analyses; SNPs represent-
ing each of these three independent signals were taken
forward for additional de novo genotyping using indepen-
dent samples. As the recent GENIE genome-wide association
study [7] identified more significant hits with end-stage renal
disease, all independent signals observed for end-stage renal
disease (n = 7; Table 1) were also de novo genotyped in a
Danish cohort of 588 individuals. Four SNPs (rs2147653,
rs7387720, rs1167726, rs7213412) in the Danish cohort
showed non-significant trends in the same direction as the
earlier results, with rs17745445 (TXNRD2 gene on
22q11.21) showing the most evidence for association.
Discussion
The mitochondrial genome is circular, is 16 569 DNA bases
in length, encodes 37 genes, and can be transcribed and
translated independently of nuclear DNA. There are several
differences between mitochondrial and nuclear genomes;
mtDNA is primarily coding (lacking introns), and has
overlapping genes, different codons, a higher mutation rate
and a greater number of copies of mtDNA present in cells
that have high energy consumption.
Previous publications have reported that SNPs in the
mitochondrial and nuclear genomes affect mitochondrial
function and have been associated with renal dysfunction
[5,6,13–16]. In the present study, none of the genotyped
SNPs in the mitochondrial genome were significantly
associated with diabetic kidney disease, but the majority
were present at very low frequency meaning that the
discovery collection was only adequately powered to
identify a statistically significant association for five of the
25 SNPs investigated. It should be noted that only 25 SNPs,
from the mitochondrial genome, were present on the
Omni1-quad array so only a limited number of mitochon-
drial SNPs were considered for their association with
diabetic kidney disease using this array-based method. It
is conceivable that more comprehensive examination of the
entire mitochondrial genome by next-generation sequencing
methods would identify hundreds of inherited and somatic
mutations and some of these mitochondrial variants may be
associated with diabetic kidney disease. Seven SNPs, repre-
senting three independent signals across five nuclear genes
(COQ5, COX6A1, GATC, TOP1MT and PARCRG) were
associated with both diabetic kidney disease and end-stage
renal disease in the discovery and in silico replication
analyses.
Six SNPs identified as associated with end-stage renal
disease and diabetic kidney disease after in silico replication
were co-located, representing one independent signal at
12q24.31. There are multiple genes within this linkage
disequilibrium block, making it challenging to identify
potential biological roles for these intronic or intergenic
mutations (Fig. S1). Coenzyme Q is an antioxidant essential
for electron-transport in the respiratory chain of the mito-
chondria; coenzyme Q5 homologue (COQ5) encodes methyl-
transferase. Cytochrome c oxidase (COX) is an enzyme,
catalysing the last step in the respiratory cycle, transferring
electrons from reduced cytochrome c to molecular oxygen.
This process is then coupled to the translocation of protons
in the inner mitochondrial membrane. A total of 13 subunits
comprise COX, of which three larger subunits are encoded
by mtDNA and the remaining 10 are encoded by nuclear
DNA [17]. COX deficiencies have been previously associated
with clinical phenotypes including neurological disorders,
Leigh syndrome, cardiomyopathy and hepatopathy [17]. The
effect of the intronic SNP located in the COX6A1 may lead
to an increase in oxidative stress within the kidney. Glutam-
yl-tRNA(Gln) amidotransferase, subunit C (GATC) is a
protein-coding gene, and clusters with long non-coding
RNA.
Two SNPS comprised a second independent signal around
the TOP1MT gene (mitochondrial topoisomerase I), which
encodes an enzyme, topoisomerase, that exclusively targets
mitochondria and plays a crucial role in the modification of
DNA [18]. TOP1MT relieves the tension of mtDNA
supercoiling generated from mtDNA transcription and rep-
lication, within the mitochondrial genome. TOP1MT is a
type 1B topoisomerase. It catalyses the temporary breaking
of the DNA and allows the DNA to turn in a controlled
rotation, before covalently linking the DNA to relax the
super coiling [18].
The third independent signal showed a consistent direction
of effect across all four collections (UK-ROI, Finnish,
American and Danish) for two intronic SNPs in the
TXNRD2 gene. This gene plays a key role in regulating
cellular redox environment, particularly scavenging of reac-
tive oxygen species in mitochondria. TNXRD2 is a stress
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response gene involved in many signalling pathways, includ-
ing WNT which is associated with renal fibrosis in diabetic
kidney disease. Gene expression of TNXRD2 is differentially
regulated by epigenetic mechanisms in response to high
glucose and is a probable target of microRNAs miR335 and
miR34a [19,20].
Complementary to the single-SNP analysis described
above, interaction analyses have produced novel findings
for common phenotypes such as cancer [21], heart disease
[22] and BMI [23], particularly when considered in asso-
ciation with environmental variables whose effects are
under genetic and epigenetic control such as smoking. It
is possible that a cumulative effect of common and/or rare
genetic variants influence diabetic kidney disease, particu-
larly where combined SNPs are located in the same
biological pathway. More comprehensive analysis of the
mitochondrial genome and genotyping in a larger popula-
tion, such as the recently funded Juvenile Diabetes Research
Foundation Genetics of Diabetic Nephropathy Collabora-
tive Research Initiative, are required to robustly consider
this approach for diabetic kidney disease. SNP–SNP inter-
action analyses for SNPs in the mitochondrial genome, did
not reveal further associations in the present study. Clusters
of correlated SNPs were identified at top-ranked genetic
loci, as shown in the supplementary regional association
plots (Figures S1–7).
Our data support the hypothesis that variants in genes
affecting mitochondrial function are associated with renal
disease including diabetic kidney disease. The identified SNPs
are found within nuclear genes implicated in the regulation
of epigenetic processes. Further research to explore the
interactions between hyperglycaemia, uraemia and epige-
netic modifications of the genome could shed new light on
how these nuclear genome SNPs are associated with the
phenotypes of diabetic kidney disease and end-stage renal
disease.
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